Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session

Patients and patient advocates raised a potentially concerning paradox at the first Medicare public listening session on the drugs that will be subject to US government price negotiations under the new Inflation Reduction Act – that the government’s ability to get lower list prices for selected drugs might lead pharmacy benefits managers to make the medications more inaccessible to patients.